A 12-MONTH COMPARATIVE CLINICAL INVESTIGATION OF 2 LOW-DOSE ORAL-CONTRACEPTIVES CONTAINING 20-MU-G ETHINYLESTRADIOL 75-MU-G GESTODENE AND 30-MU-G ETHINYLESTRADIOL 75-MU-G GESTODENE, WITH RESPECT TO EFFICACY, CYCLE CONTROL, AND TOLERANCE

The aim of this study was to compare contraceptive reliability, cycle control, and tolerance of an oral contraceptive containing 20 mu g eth inylestradiol (EE2) and 75 mu g gestodene (GSD), with a reference prep aration containing a similar dose of gestodene but in combination with 30 mu g ethinylestradiol. A higher incidence of intermenstrual bleedi ng was apparent under the 20 mu g EE2 oral contraceptive. For the 20 m u g EE2 preparation, 47.4% of all women reported spotting at least onc e over a period of 12 treatment cycles, whereas this figure was 35.5% for the 30 mu g EE2 pill (p < 0.05). However, the incidence was within a range that corresponds to that of other OCs. The cumulative breakth rough bleeding rates (at least once during the one year of treatment) of 14.5% (20 mu g EE2) and 11.8% (30 mu g EE2) of women were not signi ficantly different. In relation to all cycles, the intermenstrual blee ding rates were remarkably lower, indicating that the majority of the volunteers experienced such events only in few cycles under treatment: the spotting rate was 11.5% (20 mu g EE2) and 7.2% (30 mu g EE2) of a ll cycles, and the breakthrough bleeding rate was 2.6% and 2.6% of all cycles, respectively. Three pregnancies were recorded during the stud y (one in the 20 mu g EE2 + 75 mu g GSD group, two in the 30 mu g EE2 + 75 mu g GSD group). All three could be explained either by intake ir regularities or by circumstances impairing the contraceptive effect. T he influence of both treatments on the blood pressure and body weight proved to be extremely slight. Adverse events in both groups were rare and differences in the frequency of adverse events were not apparent. The discontinuation rate due to adverse events, including intermenstr ual bleeding, was low (9.8% for 20 mu g EE2 + 75 mu g GSD, and 7.2% fo r 30 mu g EE2 + 75 mu g GSD) and was in the lower range known for othe r oral contraceptives. Both preparations were well accepted by the vol unteers. The data obtained demonstrate clinically acceptable cycle con trol, good tolerance, and a high standard of contraceptive reliability for both drugs. Prescription of the 20 mu g EE2 preparation could be the first-line therapy in order to provide the lowest amount of EE2 po ssible. In case of persistent cycle problems, a switch to the 30 mu g EE2 drug should be considered. (C) 1997 Elsevier Science Inc.